North Lonsdale Road, Ulverston, Cumbria LA12 9DR
We are a science-led global healthcare company on a mission: we want to help people do more, feel better, live longer.
Today there are still millions of people without access to basic healthcare, thousands of diseases without adequate treatments and millions more people who suffer from everyday ailments. At GSK we want to change this.
We have three world-leading businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.
We are committed to widening access to our products, so more people can benefit, no matter where they live in the world or what they can afford to pay.
As a global healthcare company, we take on some of the world’s biggest healthcare challenges.
By delivering a sustainable business, we provide health benefits to patients and consumers, improve shareholder returns as well as supporting wider society.
Changing the face of healthcare
At GSK, we believe how we do business is as important as what we do – it’s what makes us different – so we are challenging industry norms by changing the way we work.
We have a significant global presence with commercial operations in more than 150 countries, a network of 89 manufacturing sites, and large R&D centres in the UK, USA, Belgium and China.
Our Pharmaceuticals business develops and makes medicines to treat a broad range of acute and chronic diseases. We have leading positions in respiratory disease and HIV with a portfolio of innovative and established medicines.
Our Vaccines business is one of the largest in the world, developing, producing and distributing over 1.9 million vaccines every day to people across the world. We have a broad portfolio of 39 paediatric, adolescent, adult and travel vaccines. In 2015, we distributed more than 690 million doses to over 150 countries.
Our Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health. We have a portfolio of some of the world’s most trusted and best selling brands which include Sensodyne, Voltaren, Horlicks and Panadol.
We invested £3.1 billion in 2015 in our search to develop new medicines, vaccines and consumer products.
We profiled around 40 new potential medicines and vaccines in our pipeline at our R&D event in 2015, 80 per cent of which we believe are potentially first-in-class.
We have a network of 89 manufacturing sites, and large R&D centres in the UK, US, Belgium and China.
More than 11,000 people work in R&D in our search for new medicines, vaccines and consumer healthcare products.
In 2015, we distributed more than 690 million doses of vaccines around the world.
GSK has had a factory in Ulverston since 1948. When it opened, the factory produced penicillin and one of the early visitors was the scientist who discovered the drug, Sir Alexander Fleming. The antibiotics produced in Ulverston today help save the lives of millions of people in over 100 markets worldwide.
GSK plays an active part in the local community. We take on about 10 apprentices each year, we have more than 60 members of staff who are STEM ambassadors, our staff are given time off to volunteer on local projects and we support a number of charities and organisations, such as sports clubs.
We are now preparing to build our first new manufacturing facility in the UK for over 40 years in Ulverston, alongside the existing factory.
The new factory will produce biopharmaceutical medicines. Today, about one-fifth of all pharmaceuticals are biologic in nature and GSK has a large pipeline of biologic products. Our aim is to develop a new and visionary facility, designed to deliver new pharmaceutical products and increased capacity in a state of the art 21st Century working environment. We want to develop a facility that benefits GSK, its employees and the local community.
It will be a place for long-term high value employment, attracting excellent personnel and enabling them to achieve fulfilling careers.
Work has already started to prepare the site for the new factory and we are aiming to start construction in 2017.